A Self-management Based Survivorship Intervention for Chinese Cancer Survivors
Launched by THE UNIVERSITY OF HONG KONG · Sep 6, 2022
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a special program designed to help Chinese cancer survivors manage their health after treatment. The goal is to see if this program can reduce physical symptoms, help with weight management, boost confidence in handling health issues, and improve overall quality of life for patients who have recently completed their cancer treatment. The study is currently recruiting participants aged 65 to 74 who speak Cantonese or Mandarin and have been diagnosed with a curable type of cancer.
To join the study, participants should have finished their main cancer treatments within the last six months. However, those with metastatic cancer, which means their cancer has spread to other parts of the body, are not eligible. If you participate, you can expect to engage in this self-management program and share your experiences, which will help researchers understand how to better support cancer survivors in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Cantonese- or Mandarin-speaking Chinese patients diagnosed curable cancer
- • have completed primary and adjuvant treatment within the past six months
- Exclusion Criteria:
- • Patients diagnosed with metastatic cancer
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Hong Kong, , Hong Kong
Hong Kong, , Hong Kong
Hong Kong, , Hong Kong
Hong Kong, , Hong Kong
Hong Kong, , Hong Kong
Hong Kong, , Hong Kong
Patients applied
Trial Officials
Wendy Wing Tak Lam, PhD
Principal Investigator
School of Public Health, The University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials